人脐带间充质干细胞对脊柱关节炎患者外周血T细胞产生IL-17的抑制作用

Inhibitory Effect of Human Umbilical Cord-derived Mesenchymal Stem Cells on Interleukin-17 Production in Peripheral Blood T Cells from Spondyloarthritis Patients

本研究通过观察人脐带间充质干细胞(hUCMSC)对脊柱关节炎(SpA)患者外周血T细胞产生IL-17的抑制作用,初步探索hUCMSC在SpA治疗领域的应用前景。体外分离SpA患者及健康志愿者外周血单个核细胞(PBMNC),PBMNC单独培养或与hUCMSC共培养,应用流式细胞仪检测T细胞中CD3+CD4+IL-17+(Th17)及CD3+γδTCR+IL-17+细胞比例;应用ELISA检测细胞培养上清中IL-17的浓度。结果表明,SpA患者外周血T细胞中Th17细胞占(3.42±0.82)%,CD3+γδTCR+IL-17+细胞占(0.30±0.10)%,分别是健康对照组(0.75±0.25)%和(0.06±0.02)%的4.5倍及5倍(P<0.01);SpA患者PBMNC与hUCMSC共培养后,T细胞中Th17细胞下降为(1.81±0.59)%,CD3+γδTCR+IL-17+细胞下降为(0.16±0.06)%(P<0.01);ELISA检测结果表明,SpA患者PBMNC培养上清IL-17的浓度显著高于健康对照组[(573.95±171.68)pg/ml vs(115.53±40.41)pg/ml(P<0.01)];SpA患者PBMNC与hUCMSC共培养后,细胞上清IL-17的浓度下降至(443.20±147.94)pg/ml(P<0.01)。结论:hUCMSC能够抑制SpA患者外周血T细胞产生IL-17,在SpA临床治疗中具有应用前景。

In this study, the inhibitory effect of human umbilical cord-derived mesenchymal stem cells （hUCMSC） on interleukin-17 （IL-17） production in peripheral blood T cells from patients with spondyloarthritis （SpA） were investi- gated, in order to explore the therapeutic potential of hUCMSC in the SpA. Peripheral blood mononuclear cells （PBMNC） were isolated from patients with SpA （ n = 12） and healthy subjects （ n = 6 ）. PBMNC were cultured in vitro with hUCMSC or alone. The expression of IL-17 in CD4＋ T cells or γ/δ T cells were determined in each subject group by flow cytometry. IL-17 concentrations in PBMNC culture supematantes were measured by ELISA. The results indica- ted that the proportion of IL-17-producing CD4＋ T cells and IL-17-producing γ/δ T cells of SpA patients were 4.5 folds and 5 folds of healthy controls [ CD3 ＋ CD4 ＋ IL-17 ＋ cells （ 3.42 ± 0.82） % vs （0.75 ± 0.25 ） %, P 〈 0.01 ; CD3 ＋ γδTCR ＋ IL-17 ＋ cells （0.30 ±0. 10） % vs （0.06±0.02） %, P 〈0.01 ]. After co-culture of PBMNC in patients with hUCMSC, the increased proportions of CD3 ＋ CD4 ＋ IL-17 ＋ cells and CD3 ＋ γδTCR ＋ IL-17 ＋ cells in SpA patients were inhibited signif- icantly by hUCMSC[CD3＋CD4＋IL-17＋ cells （3.42＋_0.82）% vs （1.81±0.59）% （P〈0.01）; CD3＋ γδTCR＋IL-17＋ cells （0.30 ±0. 10）% vs （0. 16 ±0.06）% （P 〈0.01]. In response to phytohemagglutinin （PHA, 1 μg/ml）, PBMNC from SpA patients secreted more IL-17 than that from healthy control [ （573.95± 171.68 ） pg/ml vs （115.53 ± 40.41 ）pg,/ml （ P 〈 0.01 ） ]. In the presence of hUCMSC, PBMNC of SpA patients produced less amount of IL-17 [ （573.95 ±171.68）pg/ml vs （443.20± 147.94） pg/ml, （P 〈 0.01 ） ]. It is concluded that the IL-17 production in peripheral blood T cells from SpA patients can be inhibited by hUCMSC, which have therapeutic potential for SpA.